Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, calls, and the like has, of course, returned. The world, after all, keeps spinning, yes? Not surprisingly, our response is to fire up the coffee kettle and prepare a few cups of stimulation. Feel free to join us. Remember, no prescription is required, so no mysterious rebates are involved. Meanwhile, here are a few tidbits to help you along. Hope your day is smashing and do stay in touch. …

The Japanese health ministry warned that the Lilly (LLY) breast cancer drug called Verzenio is suspected of adversely affecting the lungs after 14 patients developed a serious lung disease, The Japan Times reports. The drug is suspected of causing the side effects in at least four of the 14 cases, including one fatality. The drug received Japanese clearance last September and debuted in November. The number of patients in Japan who have used the oral drug since its release is estimated at around 2,000.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy